{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T16:58:45Z","timestamp":1785862725199,"version":"3.56.0"},"reference-count":53,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013,7]]},"DOI":"10.1097\/gme.0b013e31827c58ab","type":"journal-article","created":{"date-parts":[[2013,2,16]],"date-time":"2013-02-16T11:34:32Z","timestamp":1361014472000},"page":"785-794","source":"Crossref","is-referenced-by-count":20,"title":["Oral salmon calcitonin protects against impaired fasting glycemia, glucose intolerance, and obesity induced by high-fat diet and ovariectomy in rats"],"prefix":"10.1097","volume":"20","author":[{"given":"Michael","family":"Feigh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kim V.","family":"Andreassen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara T.","family":"Hjuler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rasmus H.","family":"Nielsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claus","family":"Christiansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kim","family":"Henriksen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morten A.","family":"Karsdal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-14-20210211","doi-asserted-by":"crossref","first-page":"2404","DOI":"10.1210\/jc.2003-030242","article-title":"The emergence of the metabolic syndrome with menopause.","volume":"88","author":"Carr","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"key":"R2-14-20210211","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.jsbmb.2009.12.005","article-title":"Central effects of estradiol in the regulation of food intake, body weight, and adiposity.","volume":"122","author":"Brown","year":"2010","journal-title":"J Steroid Biochem Mol Biol"},{"key":"R3-14-20210211","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.maturitas.2008.02.008","article-title":"Metabolic syndrome after menopause and the role of hormones.","volume":"60","author":"Lobo","year":"2008","journal-title":"Maturitas"},{"key":"R4-14-20210211","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1258\/MI.2007.007032","article-title":"Metabolic syndrome and the menopause.","volume":"14","author":"Kaaja","year":"2008","journal-title":"Menopause Int"},{"key":"R5-14-20210211","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1007\/s11883-004-0030-9","article-title":"Antidiabetic actions of estrogen: insight from human and genetic mouse models.","volume":"6","author":"Louet","year":"2004","journal-title":"Curr Atheroscler Rep"},{"key":"R6-14-20210211","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1001\/jama.297.13.1465","article-title":"Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause.","volume":"297","author":"Rossouw","year":"2007","journal-title":"JAMA"},{"key":"R7-14-20210211","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.maturitas.2006.05.004","article-title":"Prior hormone therapy and breast cancer risk in the Womens Health Initiative randomized trial of estrogen plus progestin.","volume":"55","author":"Anderson","year":"2006","journal-title":"Maturitas"},{"key":"R8-14-20210211","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.pharmthera.2009.06.005","article-title":"Gut hormones: implications for the treatment of obesity.","volume":"124","author":"Neary","year":"2009","journal-title":"Pharmacol Ther"},{"key":"R10-14-20210211","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1055\/s-2002-34790","article-title":"The human amylin analog, pramlintide, reduces postprandial hyperglucagonemia in patients with type 2 diabetes mellitus.","volume":"34","author":"Fineman","year":"2002","journal-title":"Horm Metab Res"},{"key":"R11-14-20210211","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1046\/j.1463-1326.2003.00295.x","article-title":"Addition of pramlintide to insulin therapy lowers HbA1c in conjunction with weight loss in patients with type 2 diabetes approaching glycaemic targets.","volume":"5","author":"Hollander","year":"2003","journal-title":"Diabetes Obes Metab"},{"key":"R12-14-20210211","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1002\/dmrr.419","article-title":"Pramlintide reduces postprandial glucose excursions when added to insulin lispro in subjects with type 2 diabetes: a dose-timing study.","volume":"20","author":"Maggs","year":"2004","journal-title":"Diabetes Metab Res Rev"},{"issue":"suppl 1","key":"R13-14-20210211","doi-asserted-by":"crossref","first-page":"S24","DOI":"10.1038\/ijo.2009.13","article-title":"Control of food intake and energy expenditure by amylin-therapeutic implications.","volume":"33","author":"Lutz","year":"2009","journal-title":"Int J Obes (Lond)"},{"key":"R14-14-20210211","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.physbeh.2010.04.012","article-title":"Central amylin acts as an adiposity signal to control body weight and energy expenditure.","volume":"101","author":"Wielinga","year":"2010","journal-title":"Physiol Behav"},{"key":"R15-14-20210211","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1038\/oby.2009.184","article-title":"Enhanced weight loss with pramlintidemetreleptin: an integrated neurohormonal approach to obesity pharmacotherapy.","volume":"17","author":"Ravussin","year":"2009","journal-title":"Obesity (Silver Spring)"},{"key":"R16-14-20210211","doi-asserted-by":"crossref","first-page":"E620","DOI":"10.1152\/ajpendo.00217.2007","article-title":"Pramlintide treatment reduces 24-h caloric intake and meal sizes and improves control of eating in obese subjects: a 6-wk translational research study.","volume":"293","author":"Smith","year":"2007","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"R17-14-20210211","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.2337\/dc08-0029","article-title":"Sustained weight loss following 12-month pramlintide treatment as an adjunct to lifestyle intervention in obesity.","volume":"31","author":"Smith","year":"2008","journal-title":"Diabetes Care"},{"key":"R18-14-20210211","doi-asserted-by":"crossref","first-page":"5657","DOI":"10.1210\/en.2010-0590","article-title":"Enhanced amylin-mediated body weight loss in estradiol-deficient diet-induced obese rats.","volume":"151","author":"Trevaskis","year":"2010","journal-title":"Endocrinology"},{"key":"R19-14-20210211","doi-asserted-by":"crossref","first-page":"5855","DOI":"10.1210\/en.2006-0393","article-title":"Antiobesity effects of the -cell hormone amylin in diet-induced obese rats: effects on food intake, body weight, composition, energy expenditure, and gene expression.","volume":"147","author":"Roth","year":"2006","journal-title":"Endocrinology"},{"key":"R20-14-20210211","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1111\/j.1463-1326.2011.01425.x","article-title":"A novel oral form of salmon calcitonin improves glucose homeostasis and reduces body weight in diet-induced obese rats.","volume":"13","author":"Feigh","year":"2011","journal-title":"Diabetes Obes Metab"},{"key":"R21-14-20210211","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/S0196-9781(99)00208-9","article-title":"Amylin receptors mediate the anorectic action of salmon calcitonin (sCT).","volume":"21","author":"Lutz","year":"2000","journal-title":"Peptides"},{"key":"R22-14-20210211","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/0091-3057(80)90196-3","article-title":"Calcitonin reduces feeding in man, monkey and rat.","volume":"12","author":"Perlow","year":"1980","journal-title":"Pharmacol Biochem Behav"},{"key":"R23-14-20210211","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/S0031-9384(02)00655-8","article-title":"Effects of amylin and salmon calcitonin on feeding and drinking behavior in pygmy goats.","volume":"75","author":"Del","year":"2002","journal-title":"Physiol Behav"},{"key":"R24-14-20210211","doi-asserted-by":"crossref","first-page":"R1798","DOI":"10.1152\/ajpregu.00386.2007","article-title":"Effects of intermittent intraperitoneal infusion of salmon calcitonin on food intake and adiposity in obese rats.","volume":"293","author":"Chelikani","year":"2007","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"issue":"pt 3","key":"R25-14-20210211","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1113\/jphysiol.2002.018671","article-title":"Salmon calcitonina potent inhibitor of food intake in states of impaired leptin signalling in laboratory rodents.","volume":"541","author":"Eiden","year":"2002","journal-title":"J Physiol"},{"key":"R26-14-20210211","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.physbeh.2007.02.012","article-title":"The acute effect of amylin and salmon calcitonin on energy expenditure.","volume":"91","author":"Wielinga","year":"2007","journal-title":"Physiol Behav"},{"key":"R27-14-20210211","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/BF03350629","article-title":"Synthetic salmon calcitonin is not diabetogenic in patients with normal or impaired glucose metabolism.","volume":"8","author":"Giustina","year":"1985","journal-title":"J Endocrinol Invest"},{"key":"R28-14-20210211","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1177\/193229680900300322","article-title":"Oral insulin: the rationale for this approach and current developments.","volume":"3","author":"Arbit","year":"2009","journal-title":"J Diabetes Sci Technol"},{"key":"R29-14-20210211","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1177\/0091270010372625","article-title":"Lessons learned from the development of oral calcitonin: the first tablet formulation of a protein in phase III clinical trials.","volume":"51","author":"Karsdal","year":"2011","journal-title":"J Clin Pharmacol"},{"key":"R30-14-20210211","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1152\/japplphysiol.00541.2010","article-title":"Altered estrogen receptor expression in skeletal muscle and adipose tissue of female rats fed a high-fat diet.","volume":"110","author":"Gorres","year":"2011","journal-title":"J Appl Physiol"},{"key":"R31-14-20210211","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1038\/oby.2003.65","article-title":"The estrogen antagonist EM-652 and dehydroepiandrosterone prevent diet- and ovariectomy-induced obesity.","volume":"11","author":"Lemieux","year":"2003","journal-title":"Obes Res"},{"key":"R32-14-20210211","doi-asserted-by":"crossref","first-page":"191","DOI":"10.2174\/1567201053586001","article-title":"Oral delivery of insulin with the eligen technology: mechanistic studies.","volume":"2","author":"Malkov","year":"2005","journal-title":"Curr Drug Deliv"},{"key":"R33-14-20210211","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1359\/jbmr.2002.17.8.1478","article-title":"Bioavailability and biological efficacy of a new oral formulation of salmon calcitonin in healthy volunteers.","volume":"17","author":"Buclin","year":"2002","journal-title":"J Bone Miner Res"},{"key":"R34-14-20210211","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1359\/JBMR.040715","article-title":"Safety and efficacy of a novel salmon calcitonin (sCT) technology-based oral formulation in healthy postmenopausal women: acute and 3-month effects on biomarkers of bone turnover.","volume":"19","author":"Tanko","year":"2004","journal-title":"J Bone Miner Res"},{"key":"R35-14-20210211","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.bone.2005.04.032","article-title":"Oral salmon calcitonin induced suppression of urinary collagen type II degradation in postmenopausal women: a new potential treatment of osteoarthritis.","volume":"37","author":"Bagger","year":"2005","journal-title":"Bone"},{"key":"R36-14-20210211","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1007\/BF00280883","article-title":"Homeostasis model assessment: insulin resistance and -cell function from fasting plasma glucose and insulin concentrations in man.","volume":"28","author":"Matthews","year":"1985","journal-title":"Diabetologia"},{"key":"R37-14-20210211","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1038\/sj.ijo.0801664","article-title":"The anorectic effect of a chronic peripheral infusion of amylin is abolished in area postremanucleus of the solitary tract (APNTS) lesioned rats.","volume":"25","author":"Lutz","year":"2001","journal-title":"Int J Obes Relat Metab Disord"},{"key":"R38-14-20210211","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/j.physbeh.2010.03.001","article-title":"Brainstem mechanisms of amylin-induced anorexia.","volume":"100","author":"Potes","year":"2010","journal-title":"Physiol Behav"},{"key":"R39-14-20210211","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/S0895-3988(08)60055-0","article-title":"Isoflavone regulates lipid metabolism via expression of related genes in OVX rats fed on a high-fat diet.","volume":"21","author":"Na","year":"2008","journal-title":"Biomed Environ Sci"},{"key":"R40-14-20210211","doi-asserted-by":"crossref","first-page":"R1833","DOI":"10.1152\/ajpregu.2001.281.6.R1833","article-title":"Amylin potently activates AP neurons possibly via formation of the excitatory second messenger cGMP.","volume":"281","author":"Riediger","year":"2001","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"key":"R41-14-20210211","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1111\/j.1476-5381.2012.01979.x","article-title":"Oral salmon calcitonin attenuates hyperglycaemia and preserves pancreatic -cell area and function in Zucker diabetic fatty rats.","volume":"167","author":"Feigh","year":"2012","journal-title":"Br J Pharmacol"},{"key":"R42-14-20210211","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S0006-8993(99)01697-2","article-title":"Pharmacological characterisation of amylin-related peptides activating subfornical organ neurones.","volume":"837","author":"Riediger","year":"1999","journal-title":"Brain Res"},{"key":"R43-14-20210211","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1038\/sj.ijo.0801806","article-title":"Estrogen deficiency causes central leptin insensitivity and increased hypothalamic neuropeptide Y.","volume":"25","author":"Ainslie","year":"2001","journal-title":"Int J Obes Relat Metab Disord"},{"key":"R44-14-20210211","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1677\/joe.1.05819","article-title":"Characterization of the resistance to the anorectic and endocrine effects of leptin in obesity-prone and obesity-resistant rats fed a high-fat diet.","volume":"183","author":"Tulipano","year":"2004","journal-title":"J Endocrinol"},{"key":"R45-14-20210211","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1111\/j.1463-1326.2011.01465.x","article-title":"Glucoregulatory effects and prolonged duration of action of davalintide: a novel amylinomimetic peptide.","volume":"13","author":"Mack","year":"2011","journal-title":"Diabetes Obes Metab"},{"key":"R46-14-20210211","doi-asserted-by":"crossref","first-page":"784","DOI":"10.2337\/diacare.26.3.784","article-title":"Pramlintide as an adjunct to insulin therapy improves long-term glycemic and weight control in patients with type 2 diabetes: a 1-year randomized controlled trial.","volume":"26","author":"Hollander","year":"2003","journal-title":"Diabetes Care"},{"key":"R47-14-20210211","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1007\/BF00281829","article-title":"Role of ovarian hormones in the long-term control of glucose homeostasis. Effects of insulin secretion.","volume":"19","author":"Bailey","year":"1980","journal-title":"Diabetologia"},{"key":"R48-14-20210211","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1210\/en.2008-0971","article-title":"Estrogens protect against high-fat diet-induced insulin resistance and glucose intolerance in mice.","volume":"150","author":"Riant","year":"2009","journal-title":"Endocrinology"},{"key":"R49-14-20210211","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1016\/j.peptides.2011.09.007","article-title":"Amylin effect in extrapancreatic tissues participating in glucose homeostasis, in normal, insulin-resistant and type 2 diabetic state.","volume":"32","author":"Moreno","year":"2011","journal-title":"Peptides"},{"key":"R50-14-20210211","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.2337\/db09-1414","article-title":"The glucagonostatic and insulinotropic effects of glucagon-like peptide 1 contribute equally to its glucose-lowering action.","volume":"59","author":"Hare","year":"2010","journal-title":"Diabetes"},{"key":"R51-14-20210211","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.mce.2008.08.012","article-title":"The incretin system and its role in type 2 diabetes mellitus.","volume":"297","author":"Holst","year":"2009","journal-title":"Mol Cell Endocrinol"},{"key":"R52-14-20210211","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.pharmthera.2007.08.006","article-title":"Selective 5-HT6 receptor ligands: progress in the development of a novel pharmacological approach to the treatment of obesity and related metabolic disorders.","volume":"117","author":"Heal","year":"2008","journal-title":"Pharmacol Ther"},{"key":"R53-14-20210211","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1038\/sj.bjp.0706807","article-title":"Chronic 5-HT6 receptor modulation by E-6837 induces hypophagia and sustained weight loss in diet-induced obese rats.","volume":"148","author":"Fisas","year":"2006","journal-title":"Br J Pharmacol"},{"key":"R54-14-20210211","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1016\/j.metabol.2010.12.005","article-title":"Differential effects of various fish proteins in altering body weight, adiposity, inflammatory status, and insulin sensitivity in high-fat-fed rats.","volume":"60","author":"Pilon","year":"2011","journal-title":"Metabolism"}],"container-title":["Menopause"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/journals.lww.com\/00042192-201307000-00014","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,4]],"date-time":"2022-02-04T16:20:13Z","timestamp":1643991613000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00042192-201307000-00014"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,7]]},"references-count":53,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2013]]}},"URL":"https:\/\/doi.org\/10.1097\/gme.0b013e31827c58ab","relation":{},"ISSN":["1072-3714"],"issn-type":[{"value":"1072-3714","type":"print"}],"subject":[],"published":{"date-parts":[[2013,7]]}}}